Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severel

EQS-News: ABIVAX / Key word(s): StudyAbivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease 02.02.2024 / 08:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax announces update to obefazimod Phase 2b clinical de...

Related Keywords

Paris ,France General ,France ,Sheldon Sloan ,Enregistrement Universel ,Patrick Malloy ,Regina Jehle ,Twitter ,Distribution Services ,Linkedin ,Company Phase ,Abivax Communications ,Euronext Paris ,New Drug Application ,French Autorit ,Des March ,Corporate News ,Regulatory Announcements ,